Fig. 2

CREM contributes to T cell dysregulations in JIA. a Healthy control PBMCs were transfected with control siRNA or with CREM siRNA and G-Mean of CREM expression was analyzed by flow cytometry, two-tailed paired t-test. b Representative histogram of CREM expression after transfection with control siRNA (black) or CREM siRNA (red). c-e Healthy control PBMCs were transfected with control siRNA or with CREM siRNA and stimulated with anti-CD3 and anti CD28 antibodies for 3 days, symbols present individual healthy controls incubated with different allogenic HC sera or SFs, two-tailed paired t-tests. c Percentages of IL-17⁺ cells within CD3⁺ T cells after restimulation with P/I in the presence of Brefeldin A. d Percentages of IFN-γ⁺ cells within CD3⁺ T cells after restimulation with P/I in the presence of Brefeldin. e Percentages of Foxp3⁺ cells within CD3⁺ T cells. F-H) Healthy control PBMCs were transfected with control siRNA or with CREM siRNA and incubated with 10% SF in RPMI for 24 h, two-tailed, paired t-tests were used to calculate p-values. f Percentages of IL-17⁺ cells within CD3⁺ T cells g Percentages of IFN-γ⁺ cells within CD3⁺ T cells. h Percentages of Foxp3⁺ cells within CD3⁺ T cells after restimulation with P/I in the presence of Brefeldin A. i-l PBMCs and SFMCs from JIA patients were transfected with control siRNA or with CREM siRNA and i-h) percentages of IL-17⁺ cells after restimulation with P/I in the presence of Brefeldin A, Wilcoxon matched-pairs signed rank test was used to calculate p-values and of k-l) Foxp3⁺ cells were assessed by flow cytometry after 24 h, two-tailed paired t-tests were used to calculate p-values